Ravi Salgia to Molecular Targeted Therapy
This is a "connection" page, showing publications Ravi Salgia has written about Molecular Targeted Therapy.
Connection Strength
2.996
-
Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35:e585-93.
Score: 0.467
-
Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
Score: 0.413
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S372-4.
Score: 0.377
-
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
Score: 0.169
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
Score: 0.166
-
MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
Score: 0.159
-
Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett. 2019 10 01; 461:123-131.
Score: 0.149
-
Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018 06; 14(6):359-366.
Score: 0.138
-
Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103.
Score: 0.137
-
EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
Score: 0.135
-
FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016 May 24; 7(21):31586-601.
Score: 0.120
-
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
Score: 0.118
-
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
Score: 0.110
-
Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol. 2015; 11(3):489-500.
Score: 0.109
-
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med. 2014 Jun; 3(3):681-92.
Score: 0.104
-
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Mol Carcinog. 2021 03; 60(3):213-223.
Score: 0.042
-
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
Score: 0.030
-
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
Score: 0.027
-
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
Score: 0.027